Citi analyst David Lebowitz raised the firm’s price target on Alnylam Pharmaceuticals to $266 from $265 and keeps a Buy rating on the shares. The company reported a Q2 net product revenue beat, driven by strong Amvuttra sales, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam reports Q2 EPS ($1.62), consensus ($1.72)
- Agios Pharmaceuticals announces license agreement with Alnylam
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam price target lowered to $233 from $247 at Bernstein
Questions or Comments about the article? Write to editor@tipranks.com